

FOR IMMEDIATE RELEASE

## **GlaxoSmithKline, with Premier Dalton McGuinty, Announces Manufacturing Expansion, Job Creation and Innovation Investment**

Mississauga, ON, September 29, 2005 – GlaxoSmithKline Inc. President and CEO Paul Lucas will be joined later today by The Honourable Dalton McGuinty, Premier of Ontario and Minister of Research and Innovation, in announcing a \$23 million expansion of the company's Mississauga facility, an increase of over 75 jobs and an investment in MaRS Discovery District. Mississauga Mayor Hazel McCallion, the Western GTA Convergence Centre's Dr. Ulrich Krull, and a number of Ontario's hospital, community, biotech and business leaders will also be in attendance.

"GlaxoSmithKline is proud to contribute to Ontario's robust and growing biotechnology sector," says Paul Lucas, President and CEO, GSK Inc. "Our announcements today are another example of GSK's ongoing commitment to invest in innovation and research in Ontario."

Already a leading research-based pharmaceutical manufacturer in Ontario, GSK is expanding to provide more locally-made medicines to patients in Ontario, across Canada and around the world. Due to GSK's proven success in world-class highly specialized manufacturing, the company will announce that it has been awarded new global manufacturing mandates, resulting in additional full-time jobs in Ontario, and a facility expansion of more than 7,000 square feet. These expanded capabilities are in addition to the current 75 GSK mandates to manufacture innovative medicines, which have created 600 jobs and protected them from being moved to other countries.

"Research and innovation is vital to Ontario's future prosperity - jurisdictions that tap the creativity of their people will be home to the most rewarding jobs, the strongest economies and the best quality of life. That's why we've created the new Ministry of Research and Innovation," said Ontario Premier Dalton McGuinty. "Our government is committed to doing its part and we need more companies like GlaxoSmithKline making this kind of commitment to innovation." The Premier will meet with GSK scientists for a tour of the Mississauga facility today.

"Our facility here in Mississauga produces a wide range of innovative medicines to treat children living with HIV in Africa, malaria patients in the developing world, and allergy sufferers right here at home," says Lucas. "To be successful, we rely on Ontario's highly skilled work force to provide the knowledge and ability to take an idea from the lab to the marketplace."

In 2004, GSK produced and shipped \$2 billion worth of medications, representing approximately 25 per cent of total pharmaceutical shipments produced in Canada. Eighty per cent of the medications produced at GSK's Mississauga facility are exported, many to more than 70 countries around the world.

GSK will also announce today that it will invest \$1 million over five years in MaRS, a not-for-profit corporation that brings together best-in-class science, business and academic leaders to accelerate the rate of successful commercialization of new discoveries in Canada. GSK's participation in MaRS brings research & development (R&D) and corporate staff on location in the Banting Building.

GSK's investment supports the Ontario Government's efforts to build a vibrant biotechnology sector in the province that is already home to more than half of Canada's entire biotechnology industry and has North America's third-largest regional concentration of biotechnology firms. The sector grew by approximately 65 per cent between 1996 and 1999, and is poised for future growth. "We are encouraged by the McGuinty government's investment in research and innovation," says Lucas. "Government investment in building an R&D culture in Ontario is vital to all Ontarians, as new innovations and technology will continue to enhance patient lives."

While Ontario recognizes the importance of innovation to the future of the province, GSK is also encouraged by recent movements by the Federal Government to support and protect pharmaceutical innovation in Canada.

### **Committed to Research and Development**

In 2004, GSK invested more than \$140 million in R&D activities in Canada, making the company one of the top 20 corporate contributors to R&D in the country.

Last year in Ontario alone, GSK invested approximately \$22 million in clinical studies, representing more than 60 per cent of GSK's total investment in clinical research in Canada. The \$6 million *GlaxoSmithKline Pathfinders Fund for Leaders in Health Science Research* is creating new research positions in medical schools across Ontario, helping to fight the brain drain and providing opportunities for Ontario's talented scientists and researchers.

PRIISME, GSK's community-based chronic disease management program, helps health-care providers in Ontario support patients suffering from asthma, diabetes and chronic obstructive pulmonary disease.

### **About GlaxoSmithKline**

GlaxoSmithKline Inc. – one of the world's leading research-based pharmaceutical and health-care companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. In Canada, GlaxoSmithKline is a top 20 investor in research and development, and contributed more than \$140 million in 2004 alone. For more information visit [www.gsk.ca](http://www.gsk.ca).

- 30 -

For more information, please contact:

Peter Schram/Alison Steeves  
GlaxoSmithKline  
905-819-3363

Anjum Nayyar  
NATIONAL Public Relations  
416-848-1369  
[anayyar@national.ca](mailto:anayyar@national.ca)